Corvus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRVS)

$11.27 -0.53 (-4.49 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$11.27
Today's Range$12.19 - $11.12
52-Week Range$8.27 - $22.14
Volume87,074 shs
Average Volume107,479 shs
Market Capitalization$246.6 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals logoCorvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:CRVS
  • CUSIP: N/A
  • Web: www.corvuspharma.com
Debt:
  • Current Ratio: 10.12%
  • Quick Ratio: 10.12%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $4.45 per share
  • Price / Book: 2.53
Profitability:
  • Trailing EPS: ($2.69)
  • Net Income: ($36,370,000.00)
  • Return on Equity: -48.78%
  • Return on Assets: -44.98%
Misc:
  • Employees: 44
  • Outstanding Shares: 21,040,000
 

Frequently Asked Questions for Corvus Pharmaceuticals (NASDAQ:CRVS)

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.81) by $0.19. View Corvus Pharmaceuticals' Earnings History.

Where is Corvus Pharmaceuticals' stock going? Where will Corvus Pharmaceuticals' stock price be in 2017?

4 brokers have issued 1 year price targets for Corvus Pharmaceuticals' shares. Their predictions range from $14.00 to $26.00. On average, they expect Corvus Pharmaceuticals' stock price to reach $21.67 in the next twelve months. View Analyst Ratings for Corvus Pharmaceuticals.

What are Wall Street analysts saying about Corvus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Corvus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. " (11/7/2017)
  • 2. Cowen and Company analysts commented, "CRVS has expanded its clinical trial collab with Genentech to include a Phase Ib/II trial." (5/2/2017)

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a increase in short interest in the month of October. As of October 13th, there was short interest totalling 1,293,252 shares, an increase of 39.6% from the September 29th total of 926,344 shares. Based on an average trading volume of 75,031 shares, the days-to-cover ratio is currently 17.2 days. Currently, 9.5% of the shares of the stock are short sold.

Who are some of Corvus Pharmaceuticals' key competitors?

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the folowing people:

  • Richard A. Miller M.D., Chairman of the Board, President, Chief Executive Officer (Age 66)
  • Leiv Lea, Chief Financial Officer (Age 63)
  • Jason V. Coloma Ph.D., Senior Vice President and Chief Business Officer (Age 41)
  • William Benton Jones Ph.D., Vice President of Pharmaceutical Development (Age 52)
  • Erik J. Verner Ph.D., Vice President of Chemistry Research (Age 52)
  • Ian T. Clark, Independent Director (Age 56)
  • Elisha P. Gould III, Independent Director (Age 60)
  • Steve E. Krognes, Independent Director (Age 48)
  • Peter Moldt Ph.D., Independent Director (Age 58)
  • Scott W. Morrison, Independent Director (Age 59)

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Who owns Corvus Pharmaceuticals stock?

Corvus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (4.24%), JPMorgan Chase & Co. (1.50%), Sphera Funds Management LTD. (1.05%), Point72 Asset Management L.P. (0.93%) and Dimensional Fund Advisors LP (0.10%). Company insiders that own Corvus Pharmaceuticals stock include A/S Novo, Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.

Who sold Corvus Pharmaceuticals stock? Who is selling Corvus Pharmaceuticals stock?

Corvus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Point72 Asset Management L.P., Sphera Funds Management LTD., JPMorgan Chase & Co. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Corvus Pharmaceuticals.

How do I buy Corvus Pharmaceuticals stock?

Shares of Corvus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corvus Pharmaceuticals' stock price today?

One share of Corvus Pharmaceuticals stock can currently be purchased for approximately $11.27.

How big of a company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals has a market capitalization of $246.6 million. The company earns ($36,370,000.00) in net income (profit) each year or ($2.69) on an earnings per share basis. Corvus Pharmaceuticals employs 44 workers across the globe.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Rd Ste 102, BURLINGAME, CA 94010-1311, United States. The company can be reached via phone at +1-650-9004520 or via email at [email protected]


MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $21.67 (92.25% upside)

Consensus Price Target History for Corvus Pharmaceuticals (NASDAQ:CRVS)

Price Target History for Corvus Pharmaceuticals (NASDAQ:CRVS)

Analysts' Ratings History for Corvus Pharmaceuticals (NASDAQ:CRVS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/23/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$14.00HighView Rating Details
8/8/2017WedbushReiterated RatingOutperform$26.00MediumView Rating Details
7/4/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
4/5/2017Cantor FitzgeraldReiterated RatingBuy$25.00HighView Rating Details
6/2/2016BTIG ResearchInitiated CoverageBuyN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageBuy$24.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Corvus Pharmaceuticals (NASDAQ:CRVS)

Earnings by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Earnings History by Quarter for Corvus Pharmaceuticals (NASDAQ CRVS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.81)($0.62)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.76)($0.73)ViewN/AView Earnings Details
3/10/201712/31/2016($0.52)($0.55)ViewN/AView Earnings Details
11/3/2016Q3 2016($0.45)($0.51)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.36)($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)
2017 EPS Consensus Estimate: ($2.27)
2018 EPS Consensus Estimate: ($3.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.80)($0.80)($0.80)
Q3 20171($0.85)($0.85)($0.85)
Q4 20171($0.62)($0.62)($0.62)
Q1 20181($0.76)($0.76)($0.76)
Q2 20181($0.89)($0.89)($0.89)
Q3 20181($1.01)($1.01)($1.01)
Q4 20181($0.85)($0.85)($0.85)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Corvus Pharmaceuticals (NASDAQ:CRVS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Corvus Pharmaceuticals (NASDAQ CRVS)

Institutional Ownership Percentage: 82.57%
Insider Trades by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)
Insider Trades by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Insider Trades by Quarter for Corvus Pharmaceuticals (NASDAQ CRVS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/23/2017Holdings A/S NovoMajor ShareholderBuy20,000$10.95$219,000.00View SEC Filing  
6/13/2017Richard A Md MillerInsiderBuy25,000$9.88$247,000.00View SEC Filing  
6/24/2016Orbimed Advisors LlcDirectorBuy1,000$12.98$12,980.00View SEC Filing  
6/21/2016Orbimed Advisors LlcDirectorBuy38,383$12.75$489,383.25View SEC Filing  
6/16/2016Orbimed Advisors LlcDirectorBuy20,000$12.35$247,000.00View SEC Filing  
6/10/2016Peter A ThompsonDirectorBuy50,000$12.96$648,000.00View SEC Filing  
5/20/2016Orbimed Advisors LlcDirectorBuy4,716$13.09$61,732.44View SEC Filing  
5/19/2016Peter A ThompsonDirectorBuy6,800$11.77$80,036.00View SEC Filing  
5/13/2016Richard A Md MillerCEOBuy30,300$10.00$303,000.00View SEC Filing  
5/12/2016A/S NovoMajor ShareholderBuy70,000$10.00$700,000.00View SEC Filing  
3/29/2016Adams Street Partners LlcMajor ShareholderBuy200,000$15.00$3,000,000.00View SEC Filing  
3/29/2016Peter A ThompsonDirectorBuy550,000$15.00$8,250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Corvus Pharmaceuticals (NASDAQ:CRVS)

Latest Headlines for Corvus Pharmaceuticals (NASDAQ CRVS)

Source:
DateHeadline
Corvus Pharmaceuticals Is Now Oversold (CRVS)Corvus Pharmaceuticals Is Now Oversold (CRVS)
www.thestreet.com - November 14 at 10:59 PM
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient SelectionCorvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
finance.yahoo.com - November 11 at 10:36 PM
FY2017 EPS Estimates for Corvus Pharmaceuticals, Inc. (CRVS) Increased by AnalystFY2017 EPS Estimates for Corvus Pharmaceuticals, Inc. (CRVS) Increased by Analyst
www.americanbankingnews.com - November 8 at 9:51 AM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Buy at Zacks Investment ResearchCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - November 7 at 8:26 PM
Corvus Pharmaceuticals, Inc. (CRVS) Posts  Earnings Results, Beats Expectations By $0.19 EPSCorvus Pharmaceuticals, Inc. (CRVS) Posts Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - November 3 at 5:48 PM
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results And Clinical Program UpdateCorvus Pharmaceuticals Reports Third Quarter 2017 Financial Results And Clinical Program Update
www.thestreet.com - November 2 at 6:30 PM
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program UpdateCorvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
finance.yahoo.com - November 2 at 6:30 PM
Corvus Pharmaceuticals, Inc. (CRVS) Short Interest UpdateCorvus Pharmaceuticals, Inc. (CRVS) Short Interest Update
www.americanbankingnews.com - October 28 at 1:26 AM
Oversold Conditions For Corvus Pharmaceuticals (CRVS)Oversold Conditions For Corvus Pharmaceuticals (CRVS)
www.thestreet.com - October 26 at 2:44 PM
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingCorvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - October 18 at 6:54 PM
Comparing Ionis Pharmaceuticals (IONS) & Corvus Pharmaceuticals (CRVS)Comparing Ionis Pharmaceuticals (IONS) & Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - October 17 at 4:30 PM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Hold at Zacks Investment ResearchCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 11 at 12:04 AM
Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare ConferenceCorvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 6:20 PM
Contrasting Corvus Pharmaceuticals (CRVS) and The CompetitionContrasting Corvus Pharmaceuticals (CRVS) and The Competition
www.americanbankingnews.com - September 14 at 12:26 AM
Corvus Pharmaceuticals, Inc. (CRVS) Expected to Announce Earnings of -$0.85 Per ShareCorvus Pharmaceuticals, Inc. (CRVS) Expected to Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - September 3 at 10:24 PM
UPDATE: Credit Suisse Upgrades Corvus Pharmaceuticals (CRVS) to NeutralUPDATE: Credit Suisse Upgrades Corvus Pharmaceuticals (CRVS) to Neutral
www.streetinsider.com - August 24 at 5:43 PM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Neutral at Credit Suisse GroupCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Neutral at Credit Suisse Group
www.americanbankingnews.com - August 23 at 9:42 PM
 Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Announce Earnings of -$0.85 Per Share Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - August 16 at 10:16 AM
Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare ConferenceCorvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
feeds.benzinga.com - August 11 at 8:59 PM
FY2017 Earnings Estimate for Corvus Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRVS)FY2017 Earnings Estimate for Corvus Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRVS)
www.americanbankingnews.com - August 10 at 1:16 PM
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives "Outperform" Rating from WedbushCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - August 8 at 8:56 PM
Research Analysts Set Expectations for Corvus Pharmaceuticals, Inc.s Q2 2017 Earnings (NASDAQ:CRVS)Research Analysts Set Expectations for Corvus Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:CRVS)
www.americanbankingnews.com - August 7 at 7:04 AM
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Issues  Earnings Results, Beats Estimates By $0.03 EPSCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Issues Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 5 at 2:34 PM
Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business UpdateCorvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 3 at 6:59 PM
Corvus Pharmaceuticals, Inc. (CRVS) Coverage Initiated at WedbushCorvus Pharmaceuticals, Inc. (CRVS) Coverage Initiated at Wedbush
www.americanbankingnews.com - August 2 at 5:48 PM
Contrasting Jaguar Animal Health (JAGX) and Corvus Pharmaceuticals (CRVS)Contrasting Jaguar Animal Health (JAGX) and Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - August 2 at 7:58 AM
Analyzing Corvus Pharmaceuticals (CRVS) and OncoGenex Pharmaceuticals (OGXI)Analyzing Corvus Pharmaceuticals (CRVS) and OncoGenex Pharmaceuticals (OGXI)
www.americanbankingnews.com - July 20 at 2:32 PM
Corvus Pharmaceuticals, Inc. (CRVS) to Post FY2017 Earnings of ($2.60) Per Share, Cantor Fitzgerald ForecastsCorvus Pharmaceuticals, Inc. (CRVS) to Post FY2017 Earnings of ($2.60) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - July 17 at 10:14 AM
Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-OncologyCorvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology
finance.yahoo.com - July 6 at 6:48 PM
Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology ProgramCorvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program
globenewswire.com - May 9 at 4:30 PM
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business UpdateCorvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
us.rd.yahoo.com - March 10 at 5:35 PM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial ConditionCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 10 at 5:35 PM
Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444
us.rd.yahoo.com - January 10 at 5:18 PM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other EventsCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
us.rd.yahoo.com - January 10 at 5:18 PM
4:11 pm Corvus Pharmaceuticals names Ian T. Clark to Board of Directors; Clark was the former CEO of Genetech4:11 pm Corvus Pharmaceuticals names Ian T. Clark to Board of Directors; Clark was the former CEO of Genetech
us.rd.yahoo.com - January 4 at 3:31 AM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD DisclosureCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
us.rd.yahoo.com - January 4 at 3:31 AM
Corvus Pharma (CRVS) Appoints Ian Clark to Board of DirectorsCorvus Pharma (CRVS) Appoints Ian Clark to Board of Directors
www.streetinsider.com - January 3 at 10:30 PM
ContraVir Pharma (CTRV) Announces Positive Update on CRV431 as HBV TreatmentContraVir Pharma (CTRV) Announces Positive Update on CRV431 as HBV Treatment
www.streetinsider.com - December 8 at 7:37 AM
ContraVirs Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis BContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B
www.prnewswire.com - December 8 at 7:37 AM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal OfficersCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - December 8 at 7:37 AM
Corvus Pharma (CRVS) Offers Encouraging Data from CPI-444 Combo Biomarker Phase 1/1bCorvus Pharma (CRVS) Offers Encouraging Data from CPI-444 Combo Biomarker Phase 1/1b
www.streetinsider.com - October 12 at 9:10 AM
Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMTCorvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT
www.nasdaq.com - September 19 at 9:04 AM
Gilead Has a Problem. These Three Biotechs Could Be the SolutionGilead Has a Problem. These Three Biotechs Could Be the Solution
blogs.barrons.com - July 22 at 2:08 PM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - May 5 at 4:44 PM
CORVUS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportCORVUS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 5 at 4:36 PM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - April 20 at 6:04 AM
U.S. IPO Market In Desperate Need Of Some Oxygen After Q1U.S. IPO Market In Desperate Need Of Some Oxygen After Q1
seekingalpha.com - April 12 at 3:27 PM
Corvus Pharmaceuticals To Present At AACR Annual Meeting April 16 - 20 In New OrleansCorvus Pharmaceuticals To Present At AACR Annual Meeting April 16 - 20 In New Orleans
www.thestreet.com - April 5 at 3:13 PM
[$$] IPOs: The Worst Yearly Start Since the Recession[$$] IPOs: The Worst Yearly Start Since the Recession
www.barrons.com - April 2 at 12:01 AM
[$$] IPO Market Flashes Red for Stocks[$$] IPO Market Flashes Red for Stocks
www.wsj.com - April 1 at 10:24 AM

Social Media

Financials

Chart

Corvus Pharmaceuticals (NASDAQ CRVS) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.